
簡(jiǎn)要描述:LY2090314 603288-22-8LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50s of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β respectively.
產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 603288-22-8 |
|---|---|---|---|
| 分子式 | C28H25FN6O3 | 純度 | >98% |
| 分子量 | 512.53 | 貨號(hào) | abs810372 |
| 規(guī)格 | 5mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is a potent inhibitor of glycogen syntha | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
LY2090314 603288-22-8
| 產(chǎn)品描述 | |
| 描述 | LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50s of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β respectively. |
| 純度 | >98% |
| 儲(chǔ)存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | LY 2090314;LY-2090314 |
| 外觀 | yellow to orange powder |
| 可溶性/溶解性 | DMSO : 93 mg/mL (181.5 mM) Ethanol : 2 mg/mL warmed (3.9 mM) |
| 生物活性 | |
| 靶點(diǎn) | GSK-3β;GSK-3α |
| In vitro(體外研究) | LY2090314 selectively inhibits the activity of GSK-3 by interrupting ATP binding. LY2090314 is able to stabilize β-catenin. LY2090314 shows limited efficacy as monotherapy. LY3090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer cell lines in vitro. |
| In vivo(體內(nèi)研究) | LY2090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer xenografts. |
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Stem CellsSignaling Pathways Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢

電話
微信掃一掃